EVP R&D, Chief Medical Officer
Sun, Feb 20, 2022
Feb 20
exercised or converted securities in ALKS
10,096 shares @ $0.00
Decreased holdings by -33.30%
Net across this filing: +80.00% (+13,322 shares)
Option Exercise
Sale tied to a same-time option exercise